Genotype‑Guided Tamoxifen Treatment (CYP2D6)
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 2.307 alerts
Get alerted when Policy MP 2.307 changes without checking for updates manually.
Monitor payer policy activity
This policy governs the use of CYP2D6 genotyping to guide tamoxifen management for individuals at high risk for or with breast cancer under Capital BlueCross programs (with some product-specific variations).
No material clinical or coverage changes in this revision.
Coverage Determinations
Primary coverage determination
Covered when ALL of the following are met:
Evidence includes a single randomized controlled trial, multiple meta-analyses and cohort studies with inconsistent results and methodological limitations; no trials demonstrate improved clinical outcomes with genotype-guided tamoxifen strategies.
Panel tests that include CYP450 and non-CYP450 genes (for example, the YouScript Panel or GeneSight Psychotropic panel) are beyond the scope of this evidence review and are excluded from consideration under this policy.
Genetic testing procedures identified by Procedure Codes 81226 and 0070U–0076U are classified as investigational and not covered for genetic testing to guide tamoxifen treatment.
CYP2D6 genotyping to guide tamoxifen management is classified as investigational (not medically necessary) due to insufficient evidence that testing improves health outcomes for individuals at high risk for or with breast cancer.
Coding and Procedure Codes
Provider Guidance and Action Items
Confirm product/program applicability before ordering
This policy applies only to certain Capital BlueCross products and programs and is subject to benefit variations; for example, FEP PPO members are governed by the FEP Medical Policy Manual (see referenced FEP resource). Verify applicability for the member's specific product before proceeding.
- FEP PPO: refer to the FEP Medical Policy Manual at https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-managementguidelines/medical-policies.
Verify coverage for codes 81226 and 0070U–0076U
Procedure codes 81226 and HCPCS codes 0070U–0076U are listed in the policy as investigational and not covered; providers must verify authorization requirements with the member's benefit plan because listing alone does not guarantee coverage.
- Investigational procedure codes: 81226, 0070U–0076U (policy states these are investigational and not covered).
- Identification of a code in the coding section does not denote coverage; verify member benefits and authorization requirements.
Consider alternative endocrine agents when appropriate
When tamoxifen is under consideration, consider alternative endocrine options—aromatase inhibitors for appropriate patients and raloxifene for risk reduction in postmenopausal women with osteoporosis or at high risk for invasive breast cancer.
- Raloxifene is an alternative for invasive cancer risk reduction in postmenopausal women with osteoporosis or high risk.
- Consider aromatase inhibitors where clinically appropriate as alternative endocrine therapy.
Verify member benefits and contact Provider/Member Services for coverage questions
These policies do not guarantee coverage or payment; providers are responsible for member-specific benefit verification and for directing clinical care. Contact Capital BlueCross Provider Services or Member Services with questions about coverage determinations.
- Payment of claims is subject to member benefit program and eligibility on date of service and medical necessity determinations.
- Policies are not a substitute for medical advice and are subject to change.
Ensure testing laboratory meets CLIA high-complexity requirements
Clinical laboratories performing CYP2D6 genotyping must meet CLIA regulatory standards; laboratory-developed tests must be licensed by CLIA for high-complexity testing. The FDA has not required regulatory review of these tests to date.
- Laboratory-developed CYP2D6 genotyping assays must meet CLIA high-complexity testing requirements.
- FDA has not required regulatory review for these tests to date; some CYP450 genotyping kits have 510(k) clearance.
Verify member eligibility, authorization, and that codes are reimbursable
Before ordering or billing, verify the member's benefit program, eligibility on the date of service, and authorization requirements; the coding list in the policy may not be all-inclusive and identification of a code does not denote coverage.
- The coding section note: list of codes may not be all-inclusive and identification of a code does not denote coverage.
- Final claim processing depends on member contract terms, benefit limitations, exclusions, and medical necessity.
Expect potential denial — CYP2D6 genotyping for tamoxifen is investigational
CYP2D6 genotyping to guide tamoxifen management is classified as investigational; such testing is subject to denial as it is not supported as medically necessary for this purpose.
- Policy statement: genotyping to determine CYP2D6 variants for managing tamoxifen is investigational due to insufficient evidence of improved health outcomes.
- Claims for CYP2D6 genotyping to guide tamoxifen treatment may be denied on that basis.
Anticipate claim denials for listed investigational procedure codes
Procedures identified by codes 81226 and 0070U–0076U are listed as investigational and not covered; claims billed with these procedure codes may be denied.
Background and Rationale
Tamoxifen is a prodrug that is metabolized to active metabolites (notably endoxifen) primarily via CYP2D6. Variants in CYP2D6 and concomitant use of potent CYP2D6 inhibitors (for example, fluoxetine or paroxetine) can substantially alter endoxifen concentrations, which led to the hypothesis that CYP2D6 genotype might influence tamoxifen effectiveness.
Clinical evidence from randomized trials, meta-analyses, and cohort studies is inconsistent and limited; the policy determined there is insufficient evidence that genotype-guided management of tamoxifen improves patient health outcomes. As a result, genotyping for CYP2D6 to guide tamoxifen therapy is considered investigational.
Additionally, several diagnostic genotyping panel tests that include multiple CYP450 genes or combined CYP450 and non-CYP450 targets are commercially available, but these panels are beyond the scope of the evidence review informing this policy and are not addressed as part of genotype-guided tamoxifen management.
Definitions
Step Therapy Considerations
| Management consideration | Clinical note / rationale |
|---|---|
| Review concomitant medications for potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) | Potent CYP2D6 inhibitors (notably fluoxetine and paroxetine) can reduce CYP2D6 activity and change a patient from an extensive to poor metabolizer; inhibitor use should be considered when assessing tamoxifen metabolism and may warrant avoiding these agents during tamoxifen therapy. |
| Consider alternative endocrine agents when appropriate (aromatase inhibitors; raloxifene for prevention in postmenopausal women) | Because CYP2D6 genotype and inhibitors can alter endoxifen levels and clinical response to tamoxifen, alternative endocrine therapies (for example, aromatase inhibitors in eligible patients or raloxifene for prevention in postmenopausal women) may be preferred in some contexts. |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.